390 likes | 755 Views
Anesthesia for Liver diseased and renal disease. Dr. Bundit Chintanapramote. Anatomy. : Liver : wt 1500 gm (2% of BW) : Blood flow 150 ml/100 gm/min (1500 ml/min, 25% of cardiac output) : Portal blood flow 75% (Oxygenation 50%) : Hepatic artery blood flow 25% (Oxygenation 50%) .
E N D
Anesthesia for Liver diseased and renal disease Dr. Bundit Chintanapramote
Anatomy : Liver : wt 1500 gm (2% of BW) : Blood flow 150 ml/100 gm/min (1500 ml/min, 25% of cardiac output) : Portal blood flow 75% (Oxygenation 50%) : Hepatic artery blood flow 25% (Oxygenation 50%)
Functions of the Liver • Metabolic • Glucose metabolism • Protein metabolism • Lipid metabolism • Protein synthesis • Coagulation factors II V VII X • Albumin • Pseudo cholinesterase
Functions of the Liver 3. Drug metabolism • reduce albumin • increase volume of distribution • impair phase I reaction 4. Bilirubin formation and excretion • Hyperbilirubinemia (renal dysfunction replace binding site for drugs)
Preoperative evaluation • Respiration system • Cardiovascular system • Gastrointestinal system • Renal system • CNS system • Hematological system • Metabolic and electrolyte
Preoperative assessment • CVS • 70% develop hyperdynamic circulation • increase cardiac output (CI and HR) • decrease SVR • normal or low BP (BP = COXSVR) • rhythm disturbance from electrolyte imbalance
Preoperative assessment 1. CVS • increase heart rate • down regulation of adrenergic receptors • down regulation of baroreceptors • Alcoholic cardiomyopathy
Preoperative assessment 2. Respiratory system • Restrictive lung disease from ascites or pleural effusions frequently responds to fluid removal • Intrapulmonary shunts (hypatopulmonary syndrome (HPS) hypoxia occurring in the absence of ascites or intrinsic lung disease • Ventilation – perfusion (V/Q) abnormalities
Preoperative assessment 3. Renal system • Salt retention due to secondary hyperaldosteronism Decrease effective circulatory volume Decrease renal blood flow Increase aldosterone Na retention, K depletion, metabolic acidosis
Preoperative assessment • Hepatorenal syndrome : severe liver disease : diminish effective circulatory volume : neurohumonal factors : normal histology : urine Na < 10 mEg/L • Acute tubular necrosis • Prerenal azotemic
Hepatorenal syndrome Major criteria • Chronic or acute hepatic disease and liver failure with portal hypertension • Serum creatinine level > 1.5 mg/dl or 24 hr cretinine clearance < 40 ml/min • Absence of shock, ongoing bacterial infection, recent use of nephrotoxic drugs, excessive fluid or blood loss • No sustained improvement in renal function after volume expansion with 1.5 L isotonic saline solution • Proteinuria < 500 mg/day and no ultrasonograhic evidence of renal tract or parenchyma disease
Hepatorenal syndrome Minor criteria • Urine Volume < 500 ml/day • Urine Sodium < 10 mEg/L • Urine Osmolality greater than plasma osmolality • Urine red blood cell count < 50 per high power field • Serum sodium < 130 mEg/L
Factor that care precipitate • Use of nephrotoxic medication (eg.) nonsteroidal anti-inflammatory drugs) • Acute gastrointestinal bleeding • Excessive diuresis • Excessive large – volume paracentesis • Infection (eg, spontaneous bacterial peritonitis sepsis
Preoperative assessment 4. Hematologic system 1.1 anemia ; reduce synthesis – intake, macrocytic anemia ; reduce life span – MAHA – hypersplenism ; increase loss – esophageal varices
Preoperative assessment 1.2 coagulopathy ; platelet quantitative and qualitative platelet defects (splenic sequestration, low levees of thrombopoietin from liver, sepsis bone marrow suppression, DIC (consumption) ; Vit K deficiency ; reduce synthesis of coagulation factors (check PT, PTT), factor VII (T½ 4-8 hr) ; 10% and 20% of patients with end-stage liver disease show baseline enhanced fibrinolysis
Preoperative assessment 5. CNS ; hepatic encephalopathy ; ammonia level ; 90 % mortality ; GABA receptor ; cerebral edema
Drug handling in liver disease 1. Biotransformation ; phase I reaction – oxidation reduction from water soluble substance (halogenated inhalation, BZP, narcotics) ; phase II reaction – conjugation to glucoronide (propofol, morphine, lorazepam, oxazepam) 2. Protein binding ; reduce albumin 3. Volume of distribution (vd) ; pancuronium
Surgical risk assessment: Child’s classification as modified by Pugh PT = prothrombin time. INR = international normalised ratio.
Effects of anesthesia on the liver • Liver blood flow Ventilation ; spontaneous, IPPV, PEEP Hypoxia ; vasoconstrict, sympathetic stimulation Carbon dioxide ; normocarbia Surgery Drugs ; Volatile anesthetics ; IV anesthetic ; regional block
Effects of anesthesia on the liver 2. Liver blood flow Volatile anesthetic ; halothane hepatitis IV anesthetic agents ; no effect
Anesthetic agents 1. Premedication short acting benzodiazepine : lorazepam, midazolam avoid sedative in severe ascites encephalopathy 2. Induction normal dose except hepatic encephalopathy rapid sequence induction
Anesthetic agents 3. NMB Prolong effect pancuronium, vecuronium, rocuronium Suxamethonium Suitable for tracium, cisatracurium 4. Opioids avoid morphine alfentanyl
Anesthetic agents 5. Inhalation agent avoid N2o in severe ascites halothane reduce liver blood flow causing halothane hepatitis Isoflurane, sevoflurane, desflurane can be used safely
Anesthetic drugs in liver failure a Halothane has been rarely reported to cause hepatitis (see p143).
Renal diseaseSign and Symptoms of TURP syndrome • Cardiopulmonary Hypertension Bradycardia Dysrhythmia Respiratory distress Cyanosis Hypotension Shock Death
Hematologic and renal Hyperglycinemia Hyperammonemia Hyponatremia Hypoosmolality Hemolysis / anemia Acute renal failure Death
Central nervous system (CNS) Nausea / vomiting Confusion / restlessness Blindness Twitches / seizures Lethargy / paralysis Dilated / non reactive pupils Coma Death